Profil
Ilona C.
Enninga is currently the Chief Executive Officer at Amphera BV.
Prior to this, she held the position of Technical Director at Charles River Laboratories Den Bosch BV from 1992.
Enninga has also worked as a Research Associate at the University of Leiden, Chief Operating Officer at Immunovo BV, and Head-Genetic & Environmental Toxicology at Charles River Laboratories Den Bosch BV.
Enninga received her undergraduate degree in 1981 and her doctorate in 1986 from the University of Leiden.
Postes actifs de Ilona C. Enninga
| Sociétés | Poste | Début |
|---|---|---|
| Charles River Laboratories Den Bosch BV | Directeur Technique/Scientifique/R&D | 01/01/1992 |
Amphera BV
 Amphera BV BiotechnologyHealth Technology Amphera BV develops an immunotherapy for cancer induced by asbestos. It triggers the patient?s own immune defense system, growth of cancer cells may be stopped or inhibited. The company was founded in December 2012 and is headquartered s-Hertogenbosch, the Netherlands. | Directeur Général | - |
Anciens postes connus de Ilona C. Enninga
| Sociétés | Poste | Fin |
|---|---|---|
| University of Leiden | Corporate Officer/Principal | - |
| Charles River Laboratories Den Bosch BV | Corporate Officer/Principal | - |
Immunovo BV
 Immunovo BV BiotechnologyHealth Technology Immunovo BV develops immune therapeutics in the field of oncology. The firm's research focuses on therapeutic vaccines based on synthetic peptide antigens for which the company applies the novel and proprietary techniques in synthetic immunogen development. Its products include Sclerostin, PD1, PEPA10-adj, Gastrine, VEGF, and GnRH. The company was founded in 2009 and is headquartered in ‘s-Hertogenbosch, the Netherlands. | Directeur des opérations | - |
Formation de Ilona C. Enninga
| University of Leiden | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Immunovo BV
Immunovo BV BiotechnologyHealth Technology Immunovo BV develops immune therapeutics in the field of oncology. The firm's research focuses on therapeutic vaccines based on synthetic peptide antigens for which the company applies the novel and proprietary techniques in synthetic immunogen development. Its products include Sclerostin, PD1, PEPA10-adj, Gastrine, VEGF, and GnRH. The company was founded in 2009 and is headquartered in ‘s-Hertogenbosch, the Netherlands. | Health Technology |
| Charles River Laboratories Den Bosch BV | |
Amphera BV
Amphera BV BiotechnologyHealth Technology Amphera BV develops an immunotherapy for cancer induced by asbestos. It triggers the patient?s own immune defense system, growth of cancer cells may be stopped or inhibited. The company was founded in December 2012 and is headquartered s-Hertogenbosch, the Netherlands. | Health Technology |
